Nuvilex, Inc. Announces Legacy Biotechnologies’ Has Reached a National Sales and Marketing Agreement for Retail Distribution of Reme-Flu™

CHERRY HILL, N.J. March 22, 2010–Nuvilex, Inc. (OTC BB: NVLX), announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™ homeopathic flu remedy, has reached an agreement with Phillips Sales and Marketing to begin the national sales and marketing campaign for retail distribution of Reme-Flu™.

Phillips Sales and Marketing has been involved with both the sales and marketing of nutriceutical and cosmeceutical products in the mass market for over 20 years. They also specialize in working with small and medium size regional drugstore chains. Phillips has run several successful sales and marketing campaigns and has been able to take products from introduction into the market all the way to distribution on a national level. Through unique advertising methods, Phillips has created product demand that resulted in product placement and sales in major drug chains, some of which are comprised of several thousand stores. Legacy Biotechnologies’ goal is to have attained distribution on a national level within 9-12 months.

“We are pleased that retail distribution is about to commence on Reme-Flu™ and anticipate this year-round product will attain its own market niche with consistent annual sales growth,” stated Martin Schmieg, Chairman and CEO of Nuvilex, Inc.

About Nuvilex, Inc.
Nuvilex, Inc. is a “Green” products company. The Company’s current products include: Cinnergen™, which promotes a healthy glucose metabolism; Cinnechol™, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink®, a permanent yet more easily removable tattoo ink. In early March, 2010, the Company announced its new and exclusive focus on “Green” technologies and products, the two principal components of which will be a planned merger with Energy Innovation Group and the Company’s existing Oraphyte™ organic nematocide product line. The new mission of the Company will be to harness green technologies into real-world commercial applications that create value and profits for both makers and users.

About Legacy Biotechnologies, Inc.
Legacy Biotechnologies, Inc. is an independent, privately-owned firm specializing in research and development of nutriceutical and cosmeceutical formulations. They specialize in creating innovative and cutting-edge compounds that address all facets of health. Its president, Steve Kushner, has been working in this field for over 26 years and has created several original formulas that have been marketed both on a national basis and abroad. Mr. Kushner’s experience allows Legacy Biotechnologies, Inc. to excel at all phases of the health and nutrition industry. In addition to research and development, Legacy Biotechnologies, Inc. is also well-versed in the manufacturing process, procurement of raw materials, creation of promotional material, and marketing of products.

Safe Harbor Statement
Statements contained in this presentation that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as “intends”, “anticipates”, “believes”, “expects”, and “hopes” and involve a number of risks and uncertainties that could cause the Company’s actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.




Be the first to comment

Leave a Reply